(Q37122158)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18374272%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

review article

1 reference

title

Neurochemical approaches of cerebrospinal fluid diagnostics in neurodegenerative diseases (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18374272%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

0 references

1 reference

Markus Otto

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18374272%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

publication date

1 April 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18374272%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18374272%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

volume

44

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18374272%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18374272%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

page(s)

289-298

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18374272%20AND%20SRC:MED&resulttype=core&format=json

[Dementia syndrome and Alzheimer disease: an assessment of morbidity and annual incidence in Germany]

4 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

The prevalence of dementia: a quantitative integration of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

The question of familial meningiomas and schwannomas: NF2B or not to be?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Prevalence and severity of cognitive impairment with and without dementia in an elderly population.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Early development and progression of dementing illness in the elderly: a general-practice based study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

A typology of sub-clinical senescent cognitive disorder.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Prevalence of ageing-associated cognitive decline in an elderly population.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Age-specific incidence rates of Alzheimer's disease: the Baltimore Longitudinal Study of Aging.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Clinical-neuropathological correlations in Alzheimer's disease and related dementias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Plaque-only Alzheimer disease is usually the lewy body variant, and vice versa.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Validity of current clinical criteria for Alzheimer's disease, vascular dementia and dementia with Lewy bodies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

The preclinical phase of alzheimer disease: A 22-year prospective study of the Framingham Cohort.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

The 'preclinical phase' of probable Alzheimer's disease. A 13-year prospective study of the Framingham cohort

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Amyloid plaque core protein in Alzheimer disease and Down syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Inflammation and Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

A68: a major subunit of paired helical filaments and derivatized forms of normal Tau.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Neurodegenerative tauopathies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Diagnostic criteria for neuropathologic assessment of Alzheimer's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Neuropsychological deficits associated with diffuse Lewy body disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Characteristics of alpha-synucleinopathy in centenarians.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Report of the second dementia with Lewy body international workshop: diagnosis and treatment. Consortium on Dementia with Lewy Bodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

MRI volumetric study of dementia with Lewy bodies: a comparison with AD and vascular dementia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Differentiation of dementia with Lewy bodies from Alzheimer's disease using brain SPECT.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Pathological entity of dementia with Lewy bodies and its differentiation from Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Alpha-synuclein in Lewy bodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Frontotemporal dementia: clinicopathological correlations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Frontotemporal dementia: a review.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

[Neuropathological diagnosis of neurodegenerative and dementia diseases]

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Severity of family distress of schizophrenia--fact or artifact?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Cerebrospinal fluid analysis: disease-related data patterns and evaluation programs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Dynamics of brain-derived proteins in cerebrospinal fluid.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Flow rate of cerebrospinal fluid (CSF)--a concept common to normal blood-CSF barrier function and to dysfunction in neurological diseases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Evolution of Alzheimer's disease related cortical lesions.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Purification of tau, a microtubule-associated protein that induces assembly of microtubules from purified tubulin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Functional implications for the microtubule-associated protein tau: localization in oligodendrocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Structure and novel exons of the human tau gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Functional interactions between the proline-rich and repeat regions of tau enhance microtubule binding and assembly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Tau protein isoforms, phosphorylation and role in neurodegenerative disorders11These authors contributed equally to this work

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Regulated phosphorylation and dephosphorylation of tau protein: effects on microtubule interaction, intracellular trafficking and neurodegeneration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Detection of phosphorylated Ser262 in fetal tau, adult tau, and paired helical filament tau.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow up study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

S-100 protein concentration in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt-Jakob disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

[Tau protein. A potential biological indicator for early detection of Alzheimer disease]

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Cerebrospinal fluid tau and beta-amyloid(1-42) in dementia disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Highly increased CSF tau protein and decreased beta-amyloid (1-42) in sporadic CJD: a discrimination from Alzheimer's disease?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Use of 14-3-3 and other brain-specific proteins in CSF in the diagnosis of variant Creutzfeldt-Jakob disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer's disease patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Cerebrospinal fluid protein biomarkers for Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

CSF markers for incipient Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Dissociation between CSF total tau and tau protein phosphorylated at threonine 231 in Creutzfeldt-Jakob disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

CSF total tau, Abeta42 and phosphorylated tau protein as biomarkers for Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Total tau protein, phosphorylated tau (181p) protein, beta-amyloid(1-42), and beta-amyloid(1-40) in cerebrospinal fluid of patients with dementia with Lewy bodies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

CSF phosphorylated tau protein and mild cognitive impairment: a prospective study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Production of the Alzheimer amyloid beta protein by normal proteolytic processing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Amyloid beta protein (A beta) in Alzheimer's disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at A beta 40 or A beta 42(43).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Elevation of beta-amyloid peptide 2-42 in sporadic and familial Alzheimer's disease and its generation in PS1 knockout cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and in patients with chronic neuroinflammation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: a study in Japan.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Core biological marker candidates of Alzheimer's disease - perspectives for diagnosis, prediction of outcome and reflection of biological activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Consensus paper of the WFSBP Task Force on Biological Markers of Dementia: the role of CSF and blood analysis in the early and differential diagnosis of dementia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Decreased beta-amyloid1-42 in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Detection of single amyloid beta-protein aggregates in the cerebrospinal fluid of Alzheimer's patients by fluorescence correlation spectroscopy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Ultrasensitive detection of pathological prion protein aggregates by dual-color scanning for intensely fluorescent targets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Amyloid beta peptides in cerebrospinal fluid as profiled with surface enhanced laser desorption/ionization time-of-flight mass spectrometry: evidence of novel biomarkers in Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Amyloid beta peptide ratio 42/40 but not A beta 42 correlates with phospho-Tau in patients with low- and high-CSF A beta 40 load.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Expression of the Alzheimer protease BACE1 is suppressed via its 5'-untranslated region

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

A new multiphasic buffer system for sodium dodecyl sulfate-polyacrylamide gel electrophoresis of proteins and peptides with molecular masses 100,000-1000, and their detection with picomolar sensitivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

CSF amyloid-beta-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Validation of amyloid-beta peptides in CSF diagnosis of neurodegenerative dementias.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Genetic and biochemical markers for Alzheimer's disease: recent developments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's Disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Cerebrospinal fluid tau and beta-amyloid in Alzheimer patients, disease controls and an age-matched random sample.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

CSF Abeta42, Tau and phosphorylated Tau, APOE epsilon4 allele and MCI type in progressive MCI.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

14-3-3 proteins on the MAP

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Detection of 14-3-3 protein in the cerebrospinal fluid supports the diagnosis of Creutzfeldt-Jakob disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Cerebrospinal-fluid test for new-variant Creutzfeldt-Jakob disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Investigation of variant Creutzfeldt-Jakob disease and other human prion diseases with tonsil biopsy samples.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Clinical relevance of increased neuron-specific enolase concentration in cerebrospinal fluid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Cerebrospinal fluid concentration of neuron-specific enolase in diagnosis of Creutzfeldt-Jakob disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Correlation of astrocytic S100 beta expression with dystrophic neurites in amyloid plaques of Alzheimer's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

The sequential development of spongiform change and gliosis of scrapie in the golden Syrian hamster

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Evolution of a strain of CJD that induces BSE-like plaques.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Serum S-100 protein: a potentially useful prognostic marker in cutaneous melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

S-100 protein and neuron-specific enolase concentrations in blood as indicators of infarction volume and prognosis in acute ischemic stroke.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Release of glial tissue-specific proteins after acute stroke: A comparative analysis of serum concentrations of protein S-100B and glial fibrillary acidic protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Erythropoietin therapy for acute stroke is both safe and beneficial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Neuropsychological function in patients with increased serum levels of protein S-100 after minor head injury.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Boxing and running lead to a rise in serum levels of S-100B protein.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

14-3-3 protein, neuron-specific enolase, and S-100 protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Decrease of S100 beta protein in serum of patients with amyotrophic lateral sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

A potential cerebrospinal fluid and plasmatic marker for the diagnosis of Creutzfeldt-Jakob disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Heart fatty acid binding protein as a potential diagnostic marker for neurodegenerative diseases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Fatty acid-binding proteins of nervous tissue

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Comparative value of brain perfusion SPECT and [(123)I]MIBG myocardial scintigraphy in distinguishing between dementia with Lewy bodies and Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

The role of 123I-metaiodobenzylguanidine myocardial scintigraphy in the diagnosis of Lewy body disease in patients with dementia in a memory clinic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

A clinical role for [(123)I]MIBG myocardial scintigraphy in the distinction between dementia of the Alzheimer's-type and dementia with Lewy bodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Value of 123I-MIBG radioactivity in the differential diagnosis of DLB from AD.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Association between cardiac denervation and parkinsonism caused by alpha-synuclein gene triplication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

Identification of cDNA clones for the human microtubule-associated protein tau and chromosomal localization of the genes for tau and microtubule-associated protein 2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2007.06.012

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.YMETH.2007.06.012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18374272%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

1 reference